Banner - Collaborative Care Symposium
News
All NewsPractice Management
Media
All VideosExpert InterviewsPodcastsMedical World NewsViewpointsInsightsCase Based Roundtable SeriesCase StudiesCase of the QuarterPractice OwnershipRapid ReadoutVideo SeriesWhat’s Your WhEYE?
Conferences
Conference CoverageConference ListingConference Recaps
Blog
More
Publications
Digital EditionSupplements And Featured PublicationsiTech
Partners
Resources
Job BoardSponsored
CE

Subscribe

  • News
  • Media
  • Conferences
  • Blog
  • Publications
  • Partners
  • Resources
  • Subscribe
  • CE
  • AMD
  • Allergy
  • Blepharitis
  • COVID-19
  • Cataract
  • Comanagement
  • Comprehensive Eye Exams
  • Conjunctivitis
  • Contact Lenses
  • Cornea
  • DME
  • Diabetic Eye Disease
  • Dry Eye
  • Geographic Atrophy
  • Glasses
  • Glaucoma
  • LASIK
  • Lens Technology
  • Lid and Lash
  • Myopia
  • Nutrition
  • OCT
  • Ocular Surface Disease
  • Optic Relief
  • Patient Care
  • Pediatrics
  • Presbyopia
  • Ptosis
  • Refractive Surgery
  • Retina
  • Technology
  • Therapeutic Cataract & Refractive
Spotlight -
Geographic Atrophy|
Myopia
Advertisement

Shawn Hobbs, OD

Advertisement

Articles by Shawn Hobbs, OD

Shawn Hobbs, OD, previews the annual NOA convention, which takes place in Columbus, Ohio, from July 10 to 12, 2025.

NOA annual convention: A celebration of community and purpose

ByShawn Hobbs, OD,Emily Kaiser Maharjan, Assistant Managing Editor
July 10th 2025

Shawn Hobbs, OD, previews the annual NOA convention, which takes place in Columbus, Ohio, from July 10 to 12, 2025.

Advertisement

Latest Updated Articles

  • Shawn Hobbs, OD, previews the annual NOA convention, which takes place in Columbus, Ohio, from July 10 to 12, 2025.
    NOA annual convention: A celebration of community and purpose

    Published: July 10th 2025 | Updated:



Advertisement
Advertisement

Trending on Optometry Times - Clinical News & Expert Optometrist Insights

1

FDA approves Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for presbyopia

2

MRI study links glymphatic system dysfunction to idiopathic intracranial hypertension

3

Study finds artificial tear viscosity and shear-thinning behavior vary by formulation

4

FDA clears Novaliq’s Investigational New Drug application for NOV05

5

FDA approves NDA labeling supplement allowing re-administration of iDose TR

  • Advertise
  • About Us
  • Editorial
  • Contact Us
  • Job Board
  • Terms & Conditions
  • Privacy
  • Do not sell my Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Ophthalmology Times
  • Modern Retina
  • Optometry Times
  • Ophthalmology Times Europe
Collaborative Care Symposium
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us